Clinicopatholgic Characteristics to the Relapse on Ductal Carcinoma In Situ: Ki-67 Index as the Most Influential Prognostic Factor
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The biggest concern related to ductal carcinoma in situ (DCIS) is local recurrence and recurrence patterns. The purpose of this study was to investigate the relationship between clinicopathological factors and relapse in patients treated with DCIS. Methods: We reviewed medical records of 104 patients who were diagnosed as DCIS between January 1999 and December 2015 at a single institute. We compared and analyzed clinicopathological factors such as age at diagnosis, preoperative lesions on ultrasonography, preoperative tumor markers, operation methods in the breast, histological grade, nuclear grade, resection margin, comedonecrosis, estrogen receptor/progesterone receptor expression, human epidermal factor receptor 2/neu expression, Ki-67, postoperative implementation of adjuvant hormonal therapy, and radiotherapy by dividing them into recurrent and non-recurrent groups. Results: Seventeen patients (16.3%) of 104 patients relapsed in the ipsilateral or contralateral breast. The median follow-up period of non-relapsed group was 4.9 years (range, 0.5–19.15) and the median follow-up period of relapsed group was 3.5 years (range, 1.4–14.13). Clinicopathological factors that were significantly related to relapse were nuclear grade (p=0.022) and Ki-67 (p=0.025) based on the results of chi-square or Fisher’s exact analysis. In multivariate analysis using logistic regression, Ki-67 (p=0.021) was significantly associated with DCIS relapse. Conclusion: This study suggested that the higher Ki-67 over 14% was strongly associated with DCIS relapse.
Abstract
Purpose: The biggest concern related to ductal carcinoma in situ (DCIS) is local recurrence and recurrence patterns. The purpose of this study was to investigate the relationship between clinicopathological factors and relapse in patients treated with DCIS. Methods: We reviewed medical records of 104 patients who were diagnosed as DCIS between January 1999 and December 2015 at a single institute. We compared and analyzed clinicopathological factors such as age at diagnosis, preoperative lesions on ultrasonography, preoperative tumor markers, operation methods in the breast, histological grade, nuclear grade, resection margin, comedonecrosis, estrogen receptor/progesterone receptor expression, human epidermal factor receptor 2/neu expression, Ki-67, postoperative implementation of adjuvant hormonal therapy, and radiotherapy by dividing them into recurrent and non-recurrent groups. Results: Seventeen patients (16.3%) of 104 patients relapsed in the ipsilateral or contralateral breast. The median follow-up period of non-relapsed group was 4.9 years (range, 0.5–19.15) and the median follow-up period of relapsed group was 3.5 years (range, 1.4–14.13). Clinicopathological factors that were significantly related to relapse were nuclear grade (p=0.022) and Ki-67 (p=0.025) based on the results of chi-square or Fisher’s exact analysis. In multivariate analysis using logistic regression, Ki-67 (p=0.021) was significantly associated with DCIS relapse. Conclusion: This study suggested that the higher Ki-67 over 14% was strongly associated with DCIS relapse.
참고문헌 (22)
- Annual report of cancer statistics in Korea in 2018, "National Cancer Information Center", 20~, pp.11-1352000-000145-10 (2021)
- Bayard S, "Screening mammography mitigates breast cancer disparities through early detection of triple negative breast cancer", Clin Imaging, 80, pp.430~437 (2021)
- Cocco D, "Invasive lobular breast cancer : data to support surgical decision making", Ann Surg Oncol, 28, pp.5723~5729 (2021)
- 이은혜, "유방암 검진 권고안 개정안", 대한의사협회지, 58(5), pp.408~419 (2015), 대한의사협회[DOI]
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Koh VCY, "Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast : literature review and single-centre retrospective series", Histopathology, 74, pp.970~987 (2019)
- Sieuwerts AM, "APOBEC3B gene expression in ductal carcinoma in situ and synchronous invasive breast cancer", Cancers, 11, pp.1062~ (2019)
- Lee LA, "Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast", Am J Surg, 192, pp.416~419 (2006)
- 김정연, "Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery", Journal of Breast Cancer, 19(2), pp.185~190 (2016), 한국유방암학회
- Allison KH, "Estrogen and progesterone receptor testing in breast cancer : ASCO", CAP guideline update, 2020, pp.38, 1346~1366
- Bustreo S, "Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation : a large case series study with a long-term follow-up", Breast Cancer Res Treat, 157, pp.363~371 (2016)
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Cuzick J, "Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ : long-term results from the UK", ANZ DCIS trial, 2011, pp.12, 21~29
- Donker M, "Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ : 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial", J Clin Oncol, 31, pp.4054~4059 (2013)
- Yoonsun Choi, "Clinicopathological markers associated with recurrence in ductal carcinoma in situ of breast by age group", 대한종양외과학회지, 14(1), pp.15~20 (2018), 대한종양외과학회[DOI]
- Williams KE, "Molecular phenotypes of DCIS predict overall and invasive recurrence", Ann Oncol, 26, pp.1019~1025 (2015)
- Keong Won Yun, "Long-term Follow-up of Pure Ductal Carcinoma in situ after Breast-Conserving Surgery", Journal of Breast Disease, 7(2), pp.73~80 (2019), 한국유방암학회[DOI]
- Poulakaki N, "Ki-67 expression as a factor predicting recurrence of ductal carcinoma in situ of the breast : a systematic review and meta-analysis", Clin Breast Cancer, 18, pp.157~167. e6 (2018)
- Di Cesare P, "The relationships between HER2 overexpression and DCIS characteristics", Breast J, 23, pp.307~314 (2017)
- Guerrieri-Gonzaga A, "Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS", Int J Cancer, 139, pp.2127~2134 (2016)
- Lin CY, "Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions", Mod Pathol, 31, pp.562~568 (2018)
- Forbes JF, "Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ(IBIS-II DCIS) : a double-blind, randomised controlled trial", Lancet, 387, pp.866~873 (2016)